Heart drug may unlock safe exercise for cardiomyopathy patients

NCT ID NCT07077005

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 16 times

Summary

This study looks at whether adding a structured exercise program is safe and helpful for people with hypertrophic obstructive cardiomyopathy who are already taking the drug mavacamten. About 24 adults with mild symptoms will either do supervised exercise or continue usual care for 6 weeks. The main goal is to check safety, and researchers will also measure changes in fitness, heart function, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY, HYPERTROPHIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Technical University Munich

    RECRUITING

    Munich, Bavaria, 81675, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.